Andrea Galisova1, Daniel Jirak1, Marketa Jiratova1, Martin Hruby2, Maria Rabyk2, Aneta Pospisilova2, and Milan Hajek1
1MR Unit, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, 2Academy of Sciences, Institute of Macromolecular Chemistry, Prague, Czech Republic
An
effective cancer diagnostic and therapeutic contrast agent with suitable
properties including high specificity and safety is on high demand. In this
study, accumulation of a biocompatible and biodegradable glycogen-based
nanoprobe (GG-Gd-DOTA-Dy) was tested and compared to a commercially available
contrast agent (gadoterate meglumine). Relaxivity and MR imaging of the probe
was performed on the phantoms. The uptake of the agents was measured on the
tumor-bearing rats at several time points after the contrast agent
administration by MRI and fluorescence imaging. We found out that the novel probe is superior to a commercially
available contrast agent regarding the relaxivity and accumulation in the tumor
tissue.